Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Drug

Sirnaomics Ltd Granted FDA Approval for Phase I RSV mRNA Vaccine Study

Fineline Cube Dec 19, 2023

Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA)...

Company Drug

Roche Receives NMPA Approval for Ophthalmology BsAb Vabysmo (Farcimab) for Diabetic Macular Edema

Fineline Cube Dec 19, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has obtained marketing approval from...

Company Drug

Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar

Fineline Cube Dec 19, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Deals

Fosun Pharmaceutical Secures GHIT Fund Investment for Malaria Drug Trial

Fineline Cube Dec 18, 2023

Shanghai Fosun Pharmaceutical Co., Ltd (SHA: 600196, HKG: 2196) has received financial backing of JPY...

Company Drug

FDA Approves Pfizer-Astellas-MSD Combo Therapy for Advanced Urothelial Cancer

Fineline Cube Dec 18, 2023

Pfizer (NYSE: PFE), Astellas (TYO: 4503), and Merck, Sharp & Dohme (MSD; NYSE: MRK) have...

Medical Device Policy / Regulatory

China Releases Emergency Use Rules for Medical Devices Amid Public Health Emergencies

Fineline Cube Dec 18, 2023

The National Medical Products Administration (NMPA), National Health Commission (NHC), and Chinese Center for Disease...

Company Deals

Novo Nordisk Acquires Alkermes’ Irish Production Site for $92.5 Million to Boost GLP-1 Output

Fineline Cube Dec 18, 2023

Novo Nordisk (CPH: NOVO-B), a Danish pharmaceutical giant, has reached an agreement to acquire a...

Company Deals

Reetoo Biotechnology Boosts AI in Medical Diagnostics with $14 Million Funding Round

Fineline Cube Dec 18, 2023

Shenzhen Reetoo Biotechnology Co., Ltd, a Chinese firm at the forefront of integrating artificial intelligence...

Company Drug

Bio-Thera Solutions Gets NMPA Green Light for PD-1 Inhibitor BAT1308 in Endometrial Cancer

Fineline Cube Dec 18, 2023

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Company Deals

Mingyi Zhizao Secures $14 Million to Scale Gene Sequencing Platform and Production

Fineline Cube Dec 18, 2023

Shenzhen Mingyi Zhizao Technology Co., Ltd, a Chinese company specializing in the gene sequencing industry,...

Company

Shanghai Pharmaceuticals Hit with Anti-Monopoly Fine by Shanghai Market Supervision Bureau

Fineline Cube Dec 18, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company based in China,...

Company Deals

Youcare Pharmaceutical Partners with Sinopharm Heilongjiang to Broaden Market Presence

Fineline Cube Dec 18, 2023

Youcare Pharmaceutical Group (SHA: 688658), a China-based pharmaceutical company, has entered into a partnership with...

Company Drug

Sanofi’s Rezurock Secures Marketing Approval in China for Chronic Graft-vs-Host Disease

Fineline Cube Dec 18, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that its drug Rezurock (belumosudil), the world’s...

Company Drug

InnoCare’s TYK2 Inhibitor ICP-332 Shows Positive Results in Atopic Dermatitis Phase II Study

Fineline Cube Dec 18, 2023

Beijing InnoCare Pharma Tech Co., (HKG: 9969), a Chinese biotechnology company specializing in oncology and...

Company Drug

MSD’s Welireg Gains FDA Approval for Advanced Renal Cell Carcinoma

Fineline Cube Dec 15, 2023

The US Food and Drug Administration (FDA) has granted an indication extension approval for Merck,...

Company Deals

Bayer Partners with ClearNote Health to Explore Prostate Cancer Treatment Response

Fineline Cube Dec 15, 2023

German multinational pharmaceutical company Bayer (ETR: BAYN) has partnered with U.S. diagnostics firm ClearNote Health...

Company Drug

3D Medicines Initiates Phase III Trial for Envafolimab in NSCLC Patient

Fineline Cube Dec 15, 2023

3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the enrollment of the first...

Company Deals

BMS Partners with Terray Therapeutics for AI-Driven Drug Discovery

Fineline Cube Dec 15, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with U.S.-based Terray Therapeutics...

Company Deals

Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics

Fineline Cube Dec 15, 2023

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have...

Company Deals

VectorBuilder Partners with Sino Biological to Boost Global Biological Reagents Market

Fineline Cube Dec 15, 2023

VectorBuilder, a genetic engineering specialist based in Guangzhou and nurtured by the state-owned Guangzhou Industrial...

Posts pagination

1 … 480 481 482 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.